The estimated Net Worth of L. Becker Hewes is at least $9.13 Million dollars as of 4 June 2024. L Hewes owns over 2,424 units of Blueprint Medicines Corp stock worth over $2,554,732 and over the last 4 years L sold BPMC stock worth over $6,580,157.
L has made over 13 trades of the Blueprint Medicines Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently L sold 2,424 units of BPMC stock worth $254,302 on 4 June 2024.
The largest trade L's ever made was selling 39,030 units of Blueprint Medicines Corp stock on 31 May 2024 worth over $4,136,399. On average, L trades about 4,142 units every 65 days since 2021. As of 4 June 2024 L still owns at least 29,514 units of Blueprint Medicines Corp stock.
You can see the complete history of L Hewes stock trades at the bottom of the page.
L's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr, and Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: